Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matt Hewitt
C-H
Matt Hewitt
Wall Street Analyst
★★☆☆☆
#2165
on 13Foresight · ranked by our own returns
56%
Success Rate
-1.1%
Average Return
24 of 43 calls profitable · -9.8% vs benchmark
📈 Across the calls we could measure, roughly 56% of Matt Hewitt's ratings turned a profit when each position was held for 1 year — averaging -1.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

292 Buy 8 Hold 0 Sell
Matt's Stock Coverage 41 ratings · 2026-06-18
Company Date Position Consensus Price Target 1-Yr Return
SLP
Simulations Plus
Jun 18, 2026 HOLD Buy
+89.9% avg upside
11 analysts
$18.50
1.37% Upside
·
CERT
Certara
Jun 18, 2026 HOLD Buy
+117.0% avg upside
21 analysts
·
MXCT
MaxCyte
Jun 17, 2026 BUY Buy
+254.0% avg upside
5 analysts
·
DYAI
Dyadic International
Jun 15, 2026 BUY Buy
3 analysts
·
LFCR
Lifecore Biomedical
Jun 15, 2026 BUY Strong Buy
+74.4% avg upside
9 analysts
+0.5%
SDGR
Schrodinger
Jun 11, 2026 BUY Strong Buy
+82.0% avg upside
14 analysts
-1.0%
CYRX
CryoPort
Jun 11, 2026 BUY Strong Buy
-2.0% avg upside
15 analysts
·
OMCL
Omnicell
Jun 11, 2026 BUY Strong Buy
+38.2% avg upside
12 analysts
·
BHST
BioHarvest Sciences
Jun 08, 2026 BUY Strong Buy
+265.9% avg upside
5 analysts
·
LGND
Ligand Pharma
Jun 03, 2026 BUY Strong Buy
-18.2% avg upside
15 analysts
+12.3%
TKNO
Alpha Teknova
Jun 03, 2026 BUY Strong Buy
+181.3% avg upside
7 analysts
·
BLFS
BioLife Solutions
Jun 03, 2026 BUY Strong Buy
+13.9% avg upside
17 analysts
·
RGEN
Repligen
Jun 03, 2026 BUY Strong Buy
+27.5% avg upside
25 analysts
+0.5%
PARK
Park Dental Partners, Inc.
Jun 02, 2026 BUY Strong Buy
+19.8% avg upside
2 analysts
·
RZLT
Rezolute
Jun 02, 2026 HOLD Strong Buy
+124.7% avg upside
13 analysts
·
INFU
InfuSystem Holdings
May 19, 2026 BUY Strong Buy
+64.6% avg upside
7 analysts
-5.5%
APYX
Apyx Medical
May 08, 2026 BUY Strong Buy
+605.5% avg upside
10 analysts
$6.00
45.58% Upside
+16.1%
OABI
OmniAb
May 08, 2026 BUY Strong Buy
+276.2% avg upside
10 analysts
$7.00
221.06% Upside
+37.4%
MRVI
Maravai Lifesciences Holdings
May 08, 2026 BUY Strong Buy
+174.0% avg upside
17 analysts
$5.00
3.43% Downside
-14.4%
CDXS
Codexis
May 08, 2026 BUY Strong Buy
+305.5% avg upside
13 analysts
$9.00
259.95% Upside
-13.7%
HSTM
HealthStream
May 06, 2026 BUY Buy
+16.1% avg upside
8 analysts
$40.00
55.11% Upside
-1.1%
BZAI
Blaize Holdings
Mar 25, 2026 BUY Strong Buy
+219.9% avg upside
6 analysts
+5.7%
FLUT
Flutter Entertainment PLC
Feb 23, 2026 BUY Strong Buy
+89.4% avg upside
37 analysts
-11.5%
NOTVQ
Inotiv
Feb 06, 2026 BUY Strong Buy
+149365.1% avg upside
6 analysts
·
CSBR
Champions Oncology
Dec 16, 2025 BUY Strong Buy
+27.1% avg upside
6 analysts
$12.00
83.85% Upside
-7.9%
VUZI
Vuzix
Dec 09, 2025 BUY Strong Buy
+110.9% avg upside
8 analysts
+2.3%
CLOV
Clover Health Investments
Oct 10, 2025 BUY Hold
-27.2% avg upside
9 analysts
+34.8%
FSLY
Fastly
Jun 17, 2025 HOLD Buy
+84.0% avg upside
25 analysts
+156.4%
NEO
NeoGenomics
Apr 25, 2025 BUY Strong Buy
+46.6% avg upside
17 analysts
-19.3%
BWMN
Bowman Consulting Group
Mar 18, 2025 BUY Strong Buy
+64.1% avg upside
11 analysts
+12.5%
EHTH
Ehealth
Dec 18, 2024 BUY Hold
+874.5% avg upside
19 analysts
-37.2%
ISPC
iSpecimen
Aug 07, 2024 BUY Strong Buy
+66.6% avg upside
3 analysts
-64.0%
SRTS
Sensus Healthcare
Feb 09, 2024 BUY Strong Buy
+147.0% avg upside
8 analysts
$6.00
118.54% Upside
+50.4%
TSE:ELVA
Electrovaya
Sep 21, 2023 BUY Strong Buy
+15.7% avg upside
11 analysts
·
VIAOY
VIA optronics
Aug 30, 2023 BUY Strong Buy
+5733.4% avg upside
3 analysts
-98.4%
TDOC
Teladoc
Feb 23, 2023 HOLD Buy
+278.2% avg upside
37 analysts
-47.1%
ANGO
AngioDynamics
Oct 04, 2019 HOLD Strong Buy
+43.9% avg upside
9 analysts
$17.00
41.61% Upside
-21.2%
VIVE
Viveve Medical
Jan 18, 2019 HOLD Buy
+79999900.0% avg upside
8 analysts
$100.00
49999899.96% Upside
-99.2%
TECH
Bio-Techne
Oct 31, 2018 HOLD Strong Buy
+43.3% avg upside
21 analysts
$154.00
167.59% Upside
+25.0%
MDXG
MiMedx Group
Feb 27, 2018 BUY Strong Buy
+178.4% avg upside
17 analysts
$19.00
416.32% Upside
-59.4%
HAE
Haemonetics
Nov 08, 2017 HOLD Buy
-8.0% avg upside
17 analysts
$50.00
32.56% Downside
+112.2%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Matt Hewitt — Frequently Asked Questions
How accurate are Matt Hewitt's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Matt's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -9.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matt ranked on 13Foresight?
Matt Hewitt is currently ranked #2165 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matt cover?
Matt most recently has ratings on SLP, CERT, MXCT, DYAI, LFCR, SDGR, CYRX, OMCL, BHST, LGND, TKNO, BLFS and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.